Of all the reader emails and blog comments the Compound Buyer desk has worked through this year, one question keeps coming back more than any other. Past the catalogue size and the price tag, past the slick sites and the loud ones, who is actually doing the unglamorous work properly?
This piece is our attempt to answer that. It starts with how to actually vet a peptide company yourself, because the framework matters more than any single recommendation. Then it walks through Black and White Peptides, one of the newer UK names that came out of that process well.
The two-part shape is deliberate. There are good reasons to be wary of any article that opens with a name and a link, and good reasons to want the name eventually. Our compromise is that you get the checklist first, the case study second, and you'll have enough to use the checklist on someone else if the company we landed on doesn't suit you.
Short on time? Skip to the worked example →
Why this question matters more than it used to
The peptide market in 2026 looks very different from the one we were writing about two years ago. Regulatory attention has tightened, particularly in the UK and across the EU, and the gap between marketing copy and what's actually in the vial has become the single most important thing a buyer needs to think about.
Two forces are pulling in opposite directions. Demand from the research community has grown sharply, which has pulled a wave of new vendors into the space. At the same time, the older names that built their reputations a decade ago have, in several cases, quietly let standards slip; reused certificates, vague sourcing, customer service that bounces between an outsourced chatbot and a generic inbox. A long-standing name on the company is no longer the shortcut to confidence it once was.
For readers, that means the old heuristic (pick the company you've heard of) does not work the way it used to. The work of vetting has shifted onto the buyer.
The five things that actually separate a good company from a bad one
After several months of reader emails, supplier conversations, and a fair amount of squinting at PDFs, we've ended up with a five-point framework. We use it ourselves now. It is deliberately unglamorous.
- A test report. With a batch number. With the lab named.A real certificate of analysis (COA) comes from an independent lab, not the seller's own back room. It carries a lot number that matches the lot number on the vial. It shows HPLC data for purity, mass spectrometry confirming molecular weight, and screens for endotoxins and heavy metals. If a company will not show you a COA before purchase, or shows you a report from a lab they will not name, the question is closed. That one check sorts the lot.
- Transparent sourcing.Where is the raw peptide synthesised? Who handles the fill and finish? You will rarely get a full supply chain, but you should get more than silence. Sellers who refuse this question are usually hiding either the answer or the fact that they don't know it themselves.
- Responsive, human customer service.Pre-sale questions are the cheapest credibility test there is. Send a specific question, the kind that requires the responder to actually know the product. Time the reply. Read it carefully. A real answer from a real person looks nothing like a scripted one, and you can usually tell inside two sentences.
- Tailored guidance, not one-size-fits-all.The wider market norm is to push a default product at every enquiry. A company that takes the time to understand what a researcher is actually trying to do is a company thinking about the long term, not the next checkout.
- A track record you can verify.This is not the same as "has been around the longest". Verifiable means batch history you can look up, certificates that go back further than three months, reviews that don't all read like they were posted on the same afternoon, and consistency between what they say now and what they said a year ago.
That's the framework. It is useful even if you never click any link in this article. Save it, use it, send it to someone before they spend money.
A worked example: looking at one of the new names
To stress-test the framework, we picked one of the newer UK-based companies that kept coming up in reader emails. Black and White Peptides went through every step of the framework, and we'd been quietly watching them for a few months before we sat down to write this.
We came across them the way most readers seem to: a couple of mentions in research forums, one or two recommendations in the inbox after the last article, and a quick look at their site that did not make us immediately want to close the tab. That alone is unusual.
What they got right on testing and certificates
The COA situation was the first thing we checked, because it is the thing most likely to fall apart on inspection. We pulled certificates for several different peptides across what appeared to be different production runs, and looked for the obvious failure modes: reused PDFs, mismatched lot numbers, missing signatures, scanned images of older documents pasted into new ones, suspiciously similar timestamps across "different" batches.
We did not find them. As far as we could see, every batch we examined had its own COA, with its own lot number matching the vial, HPLC traces showing purity figures in the range you'd expect, mass spectrometry confirming molecular weight, and the standard endotoxin and heavy metal screens documented. The certificates were signed and dated. The lab is named on the documents themselves rather than abstracted behind a logo, and the verification code resolves on the lab's own site.
That sounds like a low bar, and it is. It is also a bar that a meaningful share of the wider market does not clear. We have spent enough time looking at certificates from other vendors to know that "every batch has its own properly formatted certificate from a lab that will put its name to it" is genuinely uncommon. Whatever else can be said about the company, the paperwork holds up to scrutiny across the batches we examined, and we examined several.
The customer service test
We then ran the question test. Editorial team members sent enquiries from different addresses, with different questions, at different times of day and on different days of the week. None of them mentioned Compound Buyer.
The replies came back faster than we expected. The slowest was just under three hours; most were comfortably inside the hour. More importantly, the replies were specific. Questions about handling, about reconstitution, about which products suited which research applications, came back with answers that read as if a person had read the question and thought about it, rather than pasted a paragraph from a script.
This is unglamorous to write about. It is also the single most reliable proxy we have found for the wider competence of a supplier.
Tailored plans, not off-the-shelf
The third thing that came up repeatedly, and the thing that surprised us most, was how often the response to a vague enquiry was a question back rather than a product recommendation. What are you actually trying to do? What have you used before? Have you considered this alternative for that use case?
The wider norm in the market is to take any enquiry and route it toward whatever is in stock and on the front page. Pushing back, gently, to find out what a customer actually wants is more work for the seller and noticeably better for the buyer. We do not see it often. We saw it here.
What they said when we asked them directly
After the anonymous testing, we wrote to them in our editorial capacity and asked the questions we'd been forming since the start. The replies are below, lightly edited for length only.
When we asked how they've managed to build trust this quickly in a market where most new entrants get burned, their team gave us an answer that was less about marketing than we expected. "We didn't set out to build trust quickly. We set out to answer every email in person and to put a lot number on every certificate. The trust is just what happens when you do those two things for long enough." It's a less glamorous answer than "we went viral on TikTok" and probably closer to the truth.
On customer service, the response was equally grounded. "Every enquiry comes to a person who has actually handled the products. There is no ticketing system, no outsourced chat, no first-line script. If we can't answer something, we say so and we find out." What we'd add, having tested it ourselves, is that this only works if the people answering actually know the product, and the ones answering theirs clearly do.
On tailoring, we asked what that word actually means when most companies use it as filler. "Tailored, for us, means we'd rather lose a sale than sell someone the wrong thing. Most enquiries we get end with us asking two or three questions back before we recommend anything. Some end with us telling people they don't need what they thought they needed." That tracks with what we saw across our enquiries.
On testing, we asked the question that matters most: why every batch, when plenty of competitors get away with sampling. "Sampling assumes the batches are identical. They aren't. Synthesis varies, fill varies, storage varies. Testing every batch is the only way to put a certificate on a vial and mean it. The cost of doing it is much smaller than the cost of being wrong once." It is, we think, the right answer, and the documentation backs it up.
Where they sit in the wider landscape
A few honest caveats are owed here. Black and White Peptides are not the biggest company in this space, and they are not the cheapest. Their catalogue is narrower than the longer-established sellers, and their site is less polished than the flashiest of the new ones. They also publish certificates from one named third-party laboratory rather than rotating across multiple, which is a perfectly defensible practice but not the strongest possible version of step three on our framework. We mention all this because the moment a piece like this stops mentioning limitations, it stops being useful.
What they appear to be doing, in the slice of the business we could see, is holding their corner on the things that actually matter: documentation, response, and treating each enquiry as if it was the only one that day. Those are not the things that win attention. They are the things that earn it slowly.
For a related read on how the older end of the market has handled the same pressures, our piece on how to read a certificate of analysis covers that side of the picture in more depth.
The bottom line
Peptide sourcing in 2026 is harder than it should be, and the work of vetting has fallen squarely onto the buyer. The five-point framework above is the one we use ourselves: a real test report with a batch number and a named lab, transparent sourcing, responsive human service, tailored product information, and a track record you can verify. Use it on anyone. Use it on us.
Among the newer UK names we have looked at recently, Black and White Peptides came out of the process well. Their certificates held up under scrutiny, their replies were quick and specific, and their default behaviour with new enquiries was to ask questions rather than push product. You can see their current batch certificates and contact details on their site.
We will keep covering this space at Compound Buyer. New names are arriving every month, and we'd rather you had the tools to assess them than rely on any one recommendation, including ours. If there is a company you'd like us to put through the same framework, write in. The next piece is already half-shaped by what readers have asked for, and the one after that almost certainly will be too.
